Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a shell, not an operating company. Drugs Made In America Acquisition II Corp. has no significant operations; it exists to merge with a pharmaceutical business. That means there is no durable business to analyze, no revenue, and no competitive moat today. The filed results are sparse: in fiscal Q3 2025, quarter ended 2025-09-30, net loss was $46,158; in fiscal Q2 2025, quarter ended 2025-06-30, net loss was $38,073; in FY2025 net income was $4.2M; in fiscal Q1 2026, quarter ended 2026-03-31, net income was $4.3M; and in fiscal Q2 2026, quarter ended 2026-06-30, net income was $4.4M. Those recent positives are encouraging, but without revenue they do not reveal an operating franchise. FairStock's calculations at the 2026-10-13 close of $10.19 show a 33.97 P/E, a $7.25 Graham Number, and a -40.55% margin of safety, so the quoted price is well above that conservative value estimate. The 16/100 FairStock Score and 2/9 Piotroski F-Score suggest weak quality. Free cash flow is -$1.3M TTM, a -0.2% FCF yield, and ROCE is -0.32%. The Altman Z-Score of 21.41 looks strong, but for a shell it mostly reflects balance-sheet structure, not earning power. Growth is not meaningful: the data show huge profit growth from a tiny base, yet no revenue, and Lynch category is 'none' because only one year of filed results exists. I need to see a real target, actual financials, and deal terms before judging this as a business.

In plain English: This company does not run a business yet; it is a shell set up to buy or merge with a pharmaceutical company later. It has no revenue, and while recent filings show profits, there is no operating company to judge. At $10.19, the price looks expensive compared with the limited numbers available and the low overall quality score in the data.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer